Kornimate/medical-research-clean huggingface dataset:
resistance and/or endurance training, what is most effective in prevention of cardiovascular diseases?

Conditions: Metabolic Syndrome

Summary: the aim of the present study was to evaluate the effects of aerobic interval training versus strength training or a combination of these regimes on factors comprising the metabolic syndrome in order to find the most effective exercise regime for patients with metabolic syndrome.

in the western world, approximately 25% of young to middle-aged adults have metabolic syndrome. there seem to be a strong age-dependence in the prevalence of the metabolic syndrome, but the incidence rises rapidly within adolescents and middle-aged groups and follows the development of obesity in the general population. metabolic syndrome confers an increased risk of coronary heart disease, cardiovascular disease, and premature death; therefore, effective and affordable strategies to combat the syndrome would be of great individual and social importance. despite the general agreement that moderate-intensity physical activity for a minimum of 30 min five days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min three days a week promote and maintain health, the optimal training regime to treat metabolic syndrome and its associated cardiovascular abnormalities remains uncertain.

Eligibility criteria:
inclusion criteria: * having metabolic syndrome according to international diabetes foundations definition (idf). exclusion criteria: * unstable angina pectoris * uncompensated heart failure * myocardial infarction during the past 4 weeks * complex ventricular arrhythmias * kidney failure

Keywords: exercise therapy
is anti-factor xa associated with outcome in patients with critical covid-19 on low-molecular-weight heparin?

Conditions: Covid19; Thromboembolism; Bleeding

Summary: patients with critical covid-19 are hyper-coagulable and optimal thromboprophylaxis treatment differs with stage and severity. the most commonly used drug for thromboprophylaxis in the intensive care unit (icu) is low-molecular-weight heparin (lmwh). in contrast to unfractionated heparins, the effects of lmwh usually do not require monitoring. exceptions from this are when elimination of lmwh is impaired, extremes in age and weight, to identify deviations from predicted pharmacokinetics, and if there is an unexpected clinical response. the unexpected high incidence of thromboembolic complications among patients with critical covid-19 compared to critically ill non-covid-19 patients could motivate monitoring. the activity of lmwh is monitored by quantifying the presence of anti-factor xa (afxa). the aim of this study is to investigate if the level and the monitoring frequency of afxa is associated to mortality, thrombosis and bleeding in patients with critical covid-19 treated with lmwh and therefore could be used as a potential tool to guide lmwh-treatment.


Eligibility criteria:
inclusion criteria: * patients with critical covid-19 and respiratory failure * positive sars-cov-2 test * lmwh-effect monitored by afxa, as a trough or peak value, after at least four doses at a twice daily regime exclusion criteria: * diagnosed thromboembolism or major bleeding during their covid-illness prior to icu-admission or as a reason or contributing factor for the icu-admission. * transferred to or from an icu in other hospital/region making data collection regarding baseline data/outcomes not possible

Keywords: low-molecular-weight heparin anti-factor xa critical care
assessment of predictive role of [11c] choline pet/ct on survival in prostate cancer patients with biochemical failure without androgen deprivation therapy

Conditions: Prostate Cancer

Summary: among all the patients who underwent pet/ct with choline at our institute between 2004 and 2007 to restage the prostatic disease following biochemical recovery of the disease, in this retrospective study the patients previously treated with radical prostatectomy, who present a progressive increase in the psa value in the absence of hormone therapy and of which there is knowledge of the main clinical and follow-up data, with particular attention to survival data. the pet/ct study with choline, being part of the normal standard diagnostic work-up of patients, was performed following the normal clinical protocol. with the retrospective analysis of the data, the time elapsed following the prostatectomy operation and the follow-up time after the choline pet/ct study will be evaluated and patients who died due to prostate cancer will therefore be considered. prostate cancer-specific survival, calculated as the interval between radical prostatectomy and death due to prostate cancer, will be used as the end point. the differences between prostate cancer-specific survival of patients with a positive choline pet/ct study and patients with a negative choline pet/ct study will be evaluated (log-rank test). choline pet/ct will be considered positive if pathological findings with significant tracer uptake are identified. in the subpopulation of patients with a positive choline pet/ct study, survival data will also be evaluated in relation to the site of positivity of the pet/ct study, in particular at the level of local recurrence, in the lymph node or skeletal site.


Eligibility criteria:
inclusion criteria: * patients previously treated with radical prostatectomy, with progressive increase in psa value in the absence of hormonal therapy. exclusion criteria: * \< 18 years patients
correlation of endoscopic findings and symptoms in patients undergoing the first upper gastrointestinal endoscopy

Conditions: Symptoms and Signs; Malignancy; Ulcer Peptic

Summary: endoscopy is the best means of finding early stage of upper gastrointestinal diseases, especially early cancer and benign ulcers. currently, most people still undergo upper gastrointestinal endoscopy due to discomfort, rather than a regular physical examination at a certain age. this study prospectively investigated the reason for undergoing the first upper gastrointestinal endoscopy in patients and found the correlation of endoscopic findings and symptoms.


Eligibility criteria:
inclusion criteria: * patients undergoing the first upper gastrointestinal endoscopy. exclusion criteria: * the patients had previously performed endoscopy and any esophageal, gastric or duodenal surgery. * the patients couldn't complete the questionnaire survey under the guidance of physicians at the appointment of the upper gastrointestinal endoscopy.
screening for abdominal aortic aneurysm using a portable transthoracic echocardiography among patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the prevalence of abdominal aortic aneurysm among 65 years old individuals worldwide is 1-2%. when diagnosis is confirmed by abdominal ultrasound the prevalence is 5.5% in men and 1% in women. as abdominal aortic aneurysm and coronary heart disease share common risk factors, patients with acute coronary syndrome represent a high risk population in which screening for another atherosclerotic site is recommended. patients admitted for acs undergo routinely tte. during the same study, tte may offer the opportunity to evaluate the cardiac morphology and function and to screen for abdominal aortic aneurysm. it was reported by different studies that the sensitivity of this technique was between 91-96% for aaa screening. in addition, this method is cheap, available and requires only 2-3 minutes to be added to the standard tte. we plan to examine patients admitted with acs in our intensive care unit for screening aaa by tte in subcostal views in addition to the standard tte examination.


Eligibility criteria:
inclusion criteria: * patients over 65 years old with acs. patients capable of reading, understanding and signing informed concent exclusion criteria: * suboptimal tte windows

Keywords: abdominal aortic aneurysm (aaa), echocardiography (tte), acute coronary syndrome (acs) patients over 65 years old
walking for recovery from surgery in improving quality of life in older adults with lung or gastrointestinal cancer and their family caregivers

Conditions: Adult Liver Carcinoma; Caregiver; Colorectal Carcinoma; Lung Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma

Summary: this pilot clinical trial studies how well walking for recovery from surgery works in improving quality of life in older adults with lung or gastrointestinal cancer and their family caregivers. a walking program, such as walking for recovery from surgery may help support overall well-being as a caregiver, and may help improve family member or friend's recovery from surgery.

primary objectives: i. to examine whether the intervention and telehealth approach would be feasible and acceptable. secondary objectives: i. to examine patient outcome patterns suggesting the potential efficacy of the intervention on self-efficacy, functional status (daily steps, 6-minute walk time, timed up and go), psychological distress, symptoms, and global health status. outline: patients and caregivers receive walking for recovery from surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge. after completion of study, patients and caregivers are followed up for 2 months.

Eligibility criteria:
-inclusion: * patient: diagnosis of lung or gi (colorectal, pancreas, liver) cancers * patient: scheduled to undergo surgery * patient: \>= 65 years * patient: able to read and understand english * caregiver: family member/friend identified by the patient as the primary caregiver before and after surgery * caregiver: \>= 21 years * caregiver: able to read and understand english * this study will be conducted in patients and family caregivers who are scheduled to undergo lung or gi cancer surgery treatment * there are no restrictions related to performance status or life expectancy * all subjects must have the ability to understand and the willingness to sign a written informed consent exclusion • subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
use of 68ga-dotatoc pet/ct-enterography for detection of the primary lesion in neuroendocrine tumors of the small bowel

Conditions: Small Bowel Neoplasia; Neuroendocrine (NE) Tumors

Summary: the neuroendocrine neoplasms of the small intestine (si-nens) is a relatively rare malignancy. surgical resection is the only curative treatment for the early-stage. it remains controversial its application for advanced metastatic gastroenteropancreatic neuroendocrine tumours (gep-nets). the identification of metastatic disease and tumor grade are the most important prognostic factors in advanced gepnets. therefore, precise staging and evaluation of disease burden with a reliable imaging method is crucial for determining the correct stage of the disease and consequently the correct treatment. a unique feature of neuroendocrinal tumors (nets) is the expression of somatostatin receptors (sstr) which can be targeted with radiolabeled peptides for imaging. the positron emission tomography-computed tomography (pet/ct) technique using somatostatin analogs labeled with the positron emitting isotope, 68ga (68ga-dota peptides), has been shown to offer advantages over conventional imaging modalities as well as additional important quantitative and qualitative diagnostic information. the aim of this study is to calculate the sensitivity (se), the specificity (sp), the positive and negative predictive values (ppv and npv) and the overall accuracy of 68ga-dotatoc pet/ct-enterography in detecting in primary lesion and multifocality of sinets.


Eligibility criteria:
inclusion criteria: * patients with small bowel neuroendocrine tumours * tumors with any grade (from 1 to 3) and any ki 67 percentage * patients eligible for surgical resection exclusion criteria: * patients with synchronous other oncological disease * patients with inflammatory bowel disease * patients not eligible for surgery
single-site, open-label, randomized, cross-over study in healthy chinese subjects to evaluate the bioequivalence of single-dose rotigotine transdermal patch comparing 2 different formulations

Conditions: Healthy

Summary: the primary objective of the study is to establish bioequivalence (be) of 2 different formulations of the 2 mg/24 hr (10 cm\^2) rotigotine transdermal patches in chinese subjects.

bioequivalence will be concluded if the 90 % confidence intervals (cis) for the ratio treatment a/treatment b are fully included in the acceptance range from 0.8-1.25 for auc(0-t) and auc, and within the acceptance range from 0.7 to 1.43 for cmax.

Eligibility criteria:
inclusion criteria: * an independent ethics committee (iec) approved written informed consent form is signed and dated by the subject * subject is considered reliable and capable of adhering to the protocol, visit schedule, and patch application according to the judgment of the investigator * subject is willing and able to comply with all study requirements * subject is chinese (with all 4 grandparents being of chinese origin, as well), male, and aged between 18 and 40 years (inclusive) * subject is healthy (no clinically significant findings in any of the investigations at the eligibility assessment (ea)) * subject has a body mass index between 19 kg/m² and 24 kg/m² (inclusive), and a body weight greater than or equal to 50 kg * subject agreed to practice a medically accepted method of contraception (eg, condom, spermicide) unless sexually abstinent for the duration of the study and up to 3 months after the final patch application exclusion criteria: * subject has previously participated in this study or subject has previously been assigned to treatment in a rotigotine study * subject has participated in another study of an investigational medicinal product (imp) (or a medical device) within the previous 3 months or is currently participating in another study of an imp (or a medical device) * subject has a history of diagnosis, counseling, or treatment for chronic alcohol or drug abuse within the previous 2 years * subject has a known clinically significant allergy or known or suspected clinically significant drug hypersensitivity to any components of the imp or comparable drugs that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study * subject has lifetime history of suicide attempt * subject has a history of significant skin hypersensitivity to adhesives or other transdermal products or has recently unresolved contact dermatitis * subject has an medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study * subject has a history or present condition of epilepsy and/or seizures * subject has a history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease

Keywords: rotigotine transdermal patch bioequivalence
evaluation of the radiological dose delivered to risky interventional cardiology patients (optidose)

Conditions: X-rays; Effects; Chronic Total Occlusion

Summary: the purpose of this study is therefore to study the actual doses of x-rays delivered to the patient's skin during recanalization of a coronary artery in a context of chronic total occlusion


Eligibility criteria:
inclusion criteria: * patient over 18 years-old * patient requiring intervention with a predicted risk of exceeding the radiological threshold (air kerma\> 3gy): complex coronary dilation, coronary recanalization * patient benefiting from a social protection insurance * patient having been informed and not objecting to this research exclusion criteria: * patient refusal to participate in the study * patient with known radiosensitivity factors (eg: lupus) * patient having had radiotherapy treatment of the thoracic region. * patient whose sum of radiation doses to the skin\> 0.5 gy in the thoracic region in the 3 months preceding inclusion. * patient participating in another clinical study * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant or breastfeeding woman * patient hospitalized without consent.
buccal misoprostol and intravenous tranexamic acid during emergent cesarean delivery

Conditions: Cesarean Section Complications

Summary: purpose to evaluate the effects of buccal misoprostol with or without intravenous tranexamic acid (ta) in comparison with placebo on reducing post-partum hemorrhage in pregnant women undergoing emergent cesarean section

the american congress of obstetricians and gynecologists (acog) defines postpartum hemorrhage (pph) as the loss of more than 1,000 ml after cesarean delivery. in the majority of cases, uterine atony is responsible for the occurrence of excessive bleeding during or following childbirth. the millennium development goal of reducing the maternal mortality ratio by 75 % by 2015 will remain beyond the investigator reach unless prioritize the prevention and treatment of pph in low-resource countries. consequently, the administration of uterotonic drugs during cesarean section (cs) has become essential to diminish the risk of pph and improve maternal safety. misoprostol is a prostaglandin e1 analog proven in several randomized controlled trials to be effective in preventing pph because of its strong uterotonic effects. in addition, misoprostol is inexpensive, stable at room temperature, and easy to administer. misoprostol has been broadly studied in the prevention and treatment of pph after vaginal delivery; however, its use in conjunction with cs has not been investigated as much.t he buccal route is recognized as having the greatest benefit due to its rapid uptake, long-acting effect, and greatest bioavailability compared with other routes of misoprostol administration. anti-fibrinolytic agents, such as tranexamic acid (ta), reduce the risk of death in bleeding trauma patients. on the other hand, it has been suggested that ta administration reduces blood loss and the incidence of pph in females after vaginal or elective cs. the investigators designed this study to evaluate and compare these two new therapeutic options in controlling pph following emergent cs.

Eligibility criteria:
inclusion criteria: * age \>18 years, singleton pregnancy, term gestation and decision made for a cesarean section in labor exclusion criteria: * multiple gestations * placenta praevia and placental abruption * undergoing cesarean section with general anesthesia * women undergoing cesarean section at less than 37 weeks of gestation--with a severe medical disorder * allergy to tranexamic acid or misoprostol * refuse to consent * elective cesarean section

Keywords: cesarean section tranexamic acid postpartum hemorrhage misoprostol
lateral wedge insoles with arch support in knee osteoarthritis

Conditions: Medial Knee Osteoarthritis

Summary: the purpose of this is to test lateral foot orthoses with different amount of wedging to find a model that predicts the optimal lateral inclination of foot orthosis based on biomechanical or feelings measures. this study was a cross-sectional study with patients serving as their own control. the investigators recruited 24 knee osteoarthritis. knee radiography and clinical angles measures was carried out before making orthoses, then motion analysis with an optoelectronic system was performed with each pair of foot orthoses. during motion analysis, five gait trials were carried out in each condition.


Eligibility criteria:
inclusion criteria: * symptomatic medial knee osteoarthritis (oa ; kellgren-lawrence grade i, ii or iii) according to clinical and radiological criteria of the american college of rheumatology * knee pain \> 31/100 (western ontario and mcmaster universities arthritis index - womac) * moderately active * varus knee alignment equal or superior to 2° exclusion criteria: * severe knee oa (k-l grade iv) * rheumatoid arthritis or other inflammatory arthritis * avascular necrosis * history of periarticular fracture or septic arthritis * bone metabolic disease * pigmented villonodular synovitis * cartilaginous disease * neuropathic arthropathy * synovial osteochondromatosis * total or partial knee arthroplasty * flexion contracture of ipsi- or contra-lateral knee greater than 15° * hip or ankle joint damage with mobility limitation * obesity (bmi ≥ 40) * intra-articular corticosteroids injection in the affected knee during the two previous months * reduced mobility (charnley class c)
effectiveness of ergonomic intervention

Conditions: Low Back Pain; Neck Pain; Upper Extremity; Lower Extremity

Summary: this research study aims to investigate the long term effectiveness of a workstation ergonomic intervention for work-related posture and low back pain (lbp) of video display terminal (vdt) workers

a non-randomized, crossover trial design was used with follow-up repeated 6, 12, and 30 months from baseline in the first intervention period and then beginning at 6 months following the crossover. the administrative offices in the two main buildings of the town hall of forlì, italy. the study population was composed of 400 employees, who used vdts for at least 20 hours a week, of whom we randomly selected 100 participants from each building. of the 200 initial participants, 153 completed the study; the dropouts were due to illness/injury or maternity. participants were assigned to intervention or control during the first period and then crossed over after a 30-month washout. the intervention used in this investigation was an ergonomic adjustment of the vdt workstation design. our study showed that the workstation ergonomic adjustment improved work-related posture and in reducing lbp in vdt operators among subjects who received the intervention both in the first period and in the crossover, and maintained these positive effects for at least 30 months.

Eligibility criteria:
inclusion criteria: * the study population was composed of 400 employees, who used vdts for at least 20 hours a week exclusion criteria: * subjects were excluded if pregnant or had a medical history of serious injury, spinal surgery, malignant pathology, or severe disability

Keywords: ergonomic intervention musculoskeletal disorders low back pain posture video display terminal